Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 1997

View Archived Issues

NK1 antagonist effective in rat model of focal cerebral ischemia

Attenuation of cyclophosphamide-induced bladder damage in animals by GR-203040

Inflazyme contracts Inveresk Research for IND support

New orally active immunosuppressant for combination with ciclosporin

Additional results for Bradycor in traumatic brain injury

Kosan receives NIH grant for macrolide antibiotic development

Schering-Plough seeks approval for pediatric indication of Intron A

Novastan granted priority review status by FDA

Preliminary results reported for RMP-7/carboplatin

Promising phase II results for Genzyme Transgenics' rhATIII

Pharmacia & Upjohn's urinary incontinence treatment approved in Sweden

Agents useful for BPH from Pfizer

Warner-Lambert/CoCensys develop neuroprotective agents

Osteoprotegerin: new polypeptide for bone diseases

Ribi seeks approval for melanoma vaccine in Canada

Ethnic differences in codeine's efficacy/side effects

Copaxone approved in Canada

SB-204269, an anticonvulsant with a unique mechanism of action

Resveratrol found in edible peanuts

RPR submits NDA for novel antibiotic

Nepicastat: a novel dopamine-beta-hydroxylase inhibitor for CHF

GSH prevents cisplatin-induced toxicity

Treatment for preleukemic disorder from Milkhaus enters phase III

Effects of AE-0047 on lipid profiles

CDR Therapeutics and CellGenEx merge to form Xcyte Therapies

(S)-(-)-OSU-6162 effective in monkey model of Parkinson's disease

Tolmetin eyedrop formulation evaluated in rabbits

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...